stent

Description Results NMA

MACE 0.00 [0.00; NaN]

MACE 1.00 [0.15; 6.55]

MACE 1.97 [0.18; 21.56]

MACE 0.68 [0.11; 3.99]

MACE 0.00 [0.00; NaN]

MACE 0.00 [0.00; NaN]

MACE 0.00 [0.00; NaN]

Cilostazol 200 mg qD x6 mos Aspirin 81–162 mg qD (n=62)

vs.

Ticlopidine 200 mg qD x6 mos Aspirin 81–162 mg qD (n=63)

Sample size: 62/63

Primary endpoint:

FU duration:

Cilostazol 100 mg BID x6 mos Aspirin 81 mg TID (n=25)

vs.

Ticlopidine 100 mg BID x1 mo Aspirin 81 mg TID (n=25)

Sample size: 25/25

Primary endpoint:

FU duration:

Cilostazol 100 mg BID x6 mos Aspirin 200 mg qD (n=247)

vs.

Ticlopidine 250 mg BID x4 wks Aspirin 200 mg qD (n=243)

Sample size: 247/243

Primary endpoint:

FU duration:

Cilostazol 100 mg BID x30 days Aspirin 100 mg qD (n=147)

vs.

Ticlopidine 250 mg BID x30 days Aspirin 100 mg qD (n=149)

Sample size: 147/149

Primary endpoint:

FU duration:

Cilostazol 200 mg qD x6 mos Aspirin 81 mg qD (n=65)

vs.

Ticlopidine 200 mg qD x6 mos Aspirin 81 mg qD (n=65)

Sample size: 65/65

Primary endpoint:

FU duration:

Cilostazol 200 mg qD x6mos Aspirin 81 mg qD (n=63)

vs.

Coumadin unspecified regimen Aspirin 81 mg qD (n=63)

Sample size: 63/63

Primary endpoint:

FU duration:

Cilostazol 200 mg qD unspecified durationg qD (n=30)

vs.

Aspirin 81 mg qD (n=40)

Sample size: 30/40

Primary endpoint:

FU duration:

all cause death 1.52 [0.76; 3.05]

major bleeding 2.97 [0.31; 28.51]

stroke 2.23 [0.69; 7.21]

MI 1.41 [0.54; 3.70]

definite stent thrombosis 1.24 [0.33; 4.60]

clopidogrel plus aspirin (n=1357)

vs.

aspirin alone (n=1344)

open

Parallel groups

Sample size: 1357/1344

Primary endpoint: CV death, MI

FU duration: 19.2 months

MACE 1.78 [0.67; 4.76]

MACE 1.31 [0.30; 5.83]

MACE 0.84 [0.46; 1.51]

MACE 0.00 [0.00; NaN]

Clopidogrel 75 mg qD x4 wks Aspirin 100 mg qD (n=355)

vs.

Ticlopidine 250 mg BID x4 wks Aspirin 100 mg qD (n=345)

Sample size: 355/345

Primary endpoint:

FU duration:

Clopidogrel 300mg x1, 75 mg qD x4 wks Aspirin 325 mg qDypñ ·` (n=345)

vs.

Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD (n=340)

Sample size: 345/340

Primary endpoint:

FU duration:

Clopidogrel 300 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD (n=494)

vs.

Ticlopidine 500 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD (n=522)

Sample size: 494/522

Primary endpoint:

FU duration:

Clopidogrel 300 mg x1, 75 mg qD x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD (n=37)

vs.

Ticlopidine 250 mg po BID x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD (n=31)

Sample size: 37/31

Primary endpoint:

FU duration:

all cause death 0.70 [0.27; 1.83]

Cardiovascular death 0.37 [0.10; 1.40]

MI 1.11 [0.59; 2.08]

any bleeding 1.17 [0.93; 1.49]

GUSTO severe/moderate bleeding 0.60 [0.32; 1.13]

Cardiovascular death/MI/stent thrombosis 1.01 [0.58; 1.76]

definite stent thrombosis 0.62 [0.20; 1.90]

High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) (n=1109)

vs.

regular clopidogrel dose (n=1105)

open

Parallel groups

Sample size: 1109/1105

Primary endpoint: Cardiovascular death/MI/stent thrombosis

FU duration: 6 months

MACE 0.70 [0.36; 1.36]

MACE 0.25 [0.09; 0.75]

MACE 0.31 [0.15; 0.63]

MACE 0.51 [0.25; 1.07]

MACE 0.20 [0.06; 0.69]

Ticlopidine 250 mg BID 6 wks Aspirin 100–325 mg qD (n=243)

vs.

Coumadin INR† 2.5–3.0 6 wks Aspirin 100–325 mg qD/pj (n=230)

Sample size: 243/230

Primary endpoint:

FU duration:

Ticlopidine 250 mg BID 4 wks Aspirin 100 mg BIDage/pj (n=257)

vs.

Coumadin INR 3.5–4.5 4 wks Aspirin 100 mg BID (n=260)

Sample size: 257/260

Primary endpoint:

FU duration:

Ticlopidine 500mg qD 1 mo Aspirin 325 mg qD (n=203)

vs.

Coumadin INR 2–3 x4 wks Aspirin 325 mg qDg BID (n=201)

Sample size: 203/201

Primary endpoint:

FU duration:

Ticlopidine 250 mg BID 30 days Aspirin 250 mg qD (n=177)

vs.

Coumadin INR 2.5–3.0 x30 days Aspirin 250 mg qDg qD/pj (n=173)

Sample size: 177/173

Primary endpoint:

FU duration:

Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD (n=546)

vs.

Coumadin INR 2–2.5 x4 wks Aspirin 325 mg qDBID (n=550)

Sample size: 546/550

Primary endpoint:

FU duration:

MACE 0.15 [0.05; 0.51]

MACE 1.98 [0.24; 16.40]

Ticlopidine 250 mg BID 4 wks Aspirin 325 mg qDDage/pj (n=546)

vs.

Aspirin 325 mg qD (n=557)

Sample size: 546/557

Primary endpoint:

FU duration:

Ticlopidine 250 mg BID 1 mo Aspirin 325 mg qD 5 days (n=13)

vs.

Aspirin 325 mg qD (n=103)

Sample size: 13/103

Primary endpoint:

FU duration: